Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country
- PMID: 27773614
- DOI: 10.1016/j.jhep.2016.10.015
Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country
Abstract
Background & aims: Information on the incidence, management, and prognosis of hepatocellular carcinoma (HCC) is derived from population samples, regional data, or registries. Comprehensive national evaluations within a given country are lacking. This study aimed to investigate regional variations in HCC care within France.
Methods: This observational study analysed data from French administrative databases for more than 30,000 patients with HCC diagnosed between 2009 and 2012, and followed-up until 2013. The incidence of HCC, access to surgery, and survival, at both the national level and two geographical levels (the 21 French regions and 95 French departments into which France is divided administratively), were determined. The influence on outcome of the structure of the hospital where HCC was first managed was assessed.
Results: At the national level, the median survival was 9.4months and only 22.8% of patients had curative treatment. There were marked variations between regions and departments in incidence, access to curative treatment (range 1.3-28.8% and 8.1-32.3% respectively), and in median survival (range 5.7-12.1 and 4.3-16.5months respectively). The administrative type and annual HCC-caseload of the hospital where patients were first admitted also had an independent influence on treatment and survival.
Conclusion: Despite full insurance coverage for all citizens, national measures to reduce inequities in the management of cancer patients, standardised recommendations for HCC surveillance and management, the percentage of patients undergoing curative treatment and their survival may vary four-fold depending on their postcode. The hospital in which patients are first managed has a clear influence on accessibility to both good care and survival.
Lay summary: Population-based studies have highlighted large and sometimes unexpected differences between countries in the survival of patients with malignancy. As these differences are considered to indicate the overall effectiveness of health systems, in addition to the incidence of the cancer or quality of registration, variations within a given country should be minimal. However, similar to between countries differences, this study shows differences within the same country in the incidence, curative treatment rate, and survival of patients with HCC. Evidence that access to care and survival varies within a country can strengthen the impetus for government and clinicians to address these disparities.
Keywords: Epidemiology; Hepatocellular carcinoma; Incidence; Management; Population-based study; Survival.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Comment in
-
Patients with hepatocellular carcinoma: Your address matters!J Hepatol. 2017 Mar;66(3):480-481. doi: 10.1016/j.jhep.2016.11.026. Epub 2016 Dec 10. J Hepatol. 2017. PMID: 27965157 No abstract available.
Similar articles
-
Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.Dig Dis Sci. 2020 Jan;65(1):301-311. doi: 10.1007/s10620-019-05724-1. Epub 2019 Jul 25. Dig Dis Sci. 2020. PMID: 31346950
-
Remoteness, race and social disadvantage: disparities in hepatocellular carcinoma incidence and survival in Queensland, Australia.Liver Int. 2015 Dec;35(12):2584-94. doi: 10.1111/liv.12853. Epub 2015 May 22. Liver Int. 2015. PMID: 25900432
-
Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.J Hepatol. 2006 Jan;44(1):158-66. doi: 10.1016/j.jhep.2005.10.002. Epub 2005 Nov 2. J Hepatol. 2006. PMID: 16290309
-
[Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017].Bull Cancer. 2017 Sep;104(9):752-761. doi: 10.1016/j.bulcan.2017.06.008. Epub 2017 Jul 24. Bull Cancer. 2017. PMID: 28751065 Review. French.
-
[Epidemiology of hepatocellular carcinoma in the department of Calvados].Gastroenterol Clin Biol. 1997;21(6-7):450-8. Gastroenterol Clin Biol. 1997. PMID: 9295971 Review. French.
Cited by
-
EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL.J Exp Clin Cancer Res. 2024 Jan 29;43(1):35. doi: 10.1186/s13046-024-02957-5. J Exp Clin Cancer Res. 2024. PMID: 38287371 Free PMC article.
-
Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?Diagnostics (Basel). 2022 Dec 28;13(1):91. doi: 10.3390/diagnostics13010091. Diagnostics (Basel). 2022. PMID: 36611384 Free PMC article. Review.
-
Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada.Hepat Oncol. 2024 Mar 14;10(4):HEP50. doi: 10.2217/hep-2023-0004. eCollection 2023 Dec. Hepat Oncol. 2024. PMID: 38495452 Free PMC article.
-
The Paradox of Modern Technology in Standardizing Thermal Liver Ablation: Fostering Uniformity or Diversity?Cardiovasc Intervent Radiol. 2024 Oct;47(10):1402-1406. doi: 10.1007/s00270-024-03846-2. Epub 2024 Sep 3. Cardiovasc Intervent Radiol. 2024. PMID: 39227426 Free PMC article.
-
Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis.Sci Rep. 2024 Sep 5;14(1):20720. doi: 10.1038/s41598-024-66210-x. Sci Rep. 2024. PMID: 39237521 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials